Extended Data Fig. 4: Plasma IACS-010759 concentrations in individual patients.
Dosing regimens are detailed in Fig. 1, Supplementary Table 1. a, b, Plasma IACS-010759 concentrations AML patients in (a) Cohort 1 (red) and Cohort 2 (blue), which each received QD dosing, as well as in (b) Cohort 3 (red) and Cohort 4 (blue), which each received an induction and maintenance phase. c-e, Plasma IACS-010759 concentrations in Solid Tumor (c) Cohorts 1 (blue) and 5 (orange), (d) Cohorts 2 (purple) and 4 (red), (e) Cohort 3, and (f) Cohort 6. All cohorts received induction and maintenance phases.
